Navigation Links
Second-line CML drugs evoke faster, better front-line remissions
Date:6/5/2010

HOUSTON -- Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online by the New England Journal of Medicine.

Separate international phase III clinical trials compared high-quality remissions after one year of treatment between the standard-of-care drug imatinib, also known as Gleevec, and the second-line drugs nilotinib (Tasigna) and dasatinib (Sprycel). In both trials, previously untreated CML patients who took the newer drugs reached complete cytogenetic response and major molecular response two important measures of remission -- faster than those taking imatinib. They were also less likely to have their disease progress to advanced stages.

"The second-generation CML drugs are more effective than imatinib and less toxic overall," said Hagop Kantarjian, M.D., professor and chair of The University of Texas MD Anderson Cancer Center's Department of Leukemia. Kantarjian is the corresponding author of the dasatinib study and co-author of the nilotinib study.

Drugs likely to increase survival

"We've learned in cancer therapy that it's important to use your big guns up front," Kantarjian said. "We know that achieving complete cytogenetic response or major molecular response within a year of starting treatment is associated with more favorable long-term survival. Using these second-generation drugs first will likely improve outcomes for patients with chronic myeloid leukemia."

Imatinib, a targeted therapy that blocks the activity of a fusion protein called BCR-ABL that is created by the aberrant Philadelphia chromosome, was a breakthrough drug for CML, nearly doubling the median five-year survival rate for the disease from 50 to 90 percent.

However, 30-40 percent of imatinib patients don't reach a complete cytogenetic or major
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Second-line CML drugs evoke faster response than front-line therapy
2. Patient age not a factor in use of second-line therapy for lung cancer
3. Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
4. New Drugs, New Combinations Fight Breast Cancer
5. NICE guidelines ration affordable osteoporosis drugs
6. Bone Drugs May Beat Back Breast Cancer
7. Rehabilitation for Opiate Addiction Without Maintenance Drugs
8. Review and approval of oncology and hematology drugs at FDA from 2005 to 2007
9. Fake Drugs Bought on the Web Pose Big Health Risks
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. Common antidepressant drugs linked to lactation difficulties in moms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... East Brunswick, NJ (PRWEB) September 17, 2014 ... its Static Application Security Testing (SAST) tool, at AppSec ... the 19th from 9 am to 6 pm at ... 2014 is one of the leading software security conferences ... SPARROW is a tool that provides developers and managers ...
(Date:9/17/2014)... Journal of Surgery ( IJS ) has announced that ... after 24 months published journal issues become available for all ... is to improve surgical knowledge and patient care and it ... will improve efforts to achieve this. , Professor David ... always been a great place for authors to publish and ...
(Date:9/17/2014)... coupled to a progressive decline in signal transduction and ... at Karolinska Institutet in Sweden. The finding, which is ... new molecular mechanism underlying age-related impairment of insulin-producing cells ... risk factors for many diseases, and type 2 diabetes ... an increased risk of developing type 2 diabetes if ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... In a continuing effort to protect local athletes ... Shield of the South Shore has partnered for the ... Athletic Association to treat area fields in preparation for ... dusk, prime mosquito feeding time, the exposure to mosquito-borne ... involved in outdoor athletic activities. , Rob and Lisa ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:Mechanism behind age-dependent diabetes discovered 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2
... obstacles towards progress in the developing world is the ... been seriously addressed by the public health community. ... People, Forgotten Diseases, published by ASM Press. , Some ... too long been ignored. Parasitic and bacterial diseases ...
... Ohio, April 8, 2008 Cardinal Health,Inc. (NYSE: CAH ... safety and productivity of health care, plans to release third-quarter,results ... opening of trading,on the New York Stock Exchange., The ... 1 at,8:30 a.m. EDT to discuss results of the quarter. ...
... small trial, new study finds no effect , , TUESDAY, ... don,t help prevent relapses in patients with Crohn,s disease, ... of the Journal of the American Medical Association ... lead author Dr. Brian Feagan, professor of medicine and ...
... tea have long held a place in traditional medicine in ... health and long life and for the treatment of specific ... the bodys immune functions and hold the potential for treatment ... Now a new study by Chinese scientists found that combining ...
... 8, 2008 The numbers tell the,story, Vicki Hoak, ... the Senate Aging and Youth Committee today.,The Medicaid reimbursement ... is $67,000,per person. For an acute care hospital, the ... is just $21,000., Since the Governor and legislators ...
... Light San Diego Pink Day, SAN DIEGO, April ... world,s largest grassroots network of breast cancer survivors and,activists ... San Diego Affiliate will award $960,000 in grants to ... underinsured women and men in,San Diego receive breast cancer ...
Cached Medicine News:Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 2Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 4
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... CARLSBAD, Calif. , Sept. 17, 2014 /PRNewswire/ ... ) announced that it has earned a $4 ... AKAO ) associated with the initiation of ... with serious multi-drug resistant (MDR), gram-negative bacterial infections.  ... superiority study to evaluate the efficacy and safety ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: